Corbus Pharmaceuticals Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Corbus Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 8,360,000 shares, a drop of 42.3% from the June 15th total of 14,480,000 shares. Based on an average daily volume of 3,050,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 6.8% of the company's stock are sold short.
View Corbus Pharmaceuticals' Short Interest.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its earnings results on Thursday, May, 13th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $0.65 million during the quarter, compared to analyst estimates of $0.95 million. Corbus Pharmaceuticals had a negative trailing twelve-month return on equity of 182.21% and a negative net margin of 3,460.04%.
View Corbus Pharmaceuticals' earnings history.

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP stock has decreased by 66.7% and is now trading at $1.37.
View which stocks have been most impacted by COVID-19.

6 analysts have issued twelve-month price objectives for Corbus Pharmaceuticals' stock. Their forecasts range from $2.50 to $3.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $2.88 in the next year. This suggests a possible upside of 109.9% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Corbus Pharmaceuticals include Trillium Therapeutics (TRIL), Rigel Pharmaceuticals (RIGL), Epizyme (EPZM), Crinetics Pharmaceuticals (CRNX), Adagene (ADAG), Merus (MRUS), Affimed (AFMD), Seres Therapeutics (MCRB), Kadmon (KDMN), Sesen Bio (SESN), BioXcel Therapeutics (BTAI), AnaptysBio (ANAB), Karyopharm Therapeutics (KPTI), PyroGenesis Canada (PYR) and ORIC Pharmaceuticals (ORIC).
View all of CRBP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Davy Global Fund Management Ltd (2.31%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals.

CRBP stock was acquired by a variety of institutional investors in the last quarter, including Davy Global Fund Management Ltd. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, Robert Paul Discordia, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals or or view top insider-buying stocks.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRBP stock can currently be purchased for approximately $1.37.

Corbus Pharmaceuticals has a market capitalization of $171.29 million and generates $3.94 million in revenue each year. The biopharmaceutical company earns $-111,270,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.

Corbus Pharmaceuticals employs 76 workers across the globe.

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]